TC
STLN

T3 Companies’s Starling Oncology STLN Stock Holding History

T3 Companies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Sell
80,000
-31,900
-29% -$134K 0.46% 47
2026
Q1 		$344K Sell
111,900
-89,200
-44% -$274K 0.45% 40
2025
Q4 		$716K Buy
+201,100
New +$746K 0.89% 22

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T3 Companies's STLN Position: Q2 2026 in Review

T3 Companies reduced its Starling Oncology (STLN) stake by 29% in Q2 2026, selling an estimated $134K and leaving 80,000 shares worth $434K. The position accounts for 0.46% of the portfolio, ranked #47.

T3 Companies first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. The position peaked at $716K in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • T3 Companies held 80,000 shares of Starling Oncology worth $434K as of Q2 2026.
  • T3 Companies sold 31,900 Starling Oncology shares in Q2 2026, an estimated $134K.
  • Starling Oncology made up 0.46% of T3 Companies's portfolio in Q2 2026, its #47 holding.
  • T3 Companies first reported a position in Starling Oncology in Q4 2025 and has held it in 3 quarters since.
  • T3 Companies's Starling Oncology position peaked at $716K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.